Learn more about investing in Afynia

Our team will get back to you soon to follow up on your inquiry.
Opt-In Checkbox
Explain the Pain
Funding to Date*
* Data source: Crunchbase
Lauren Foster, PhD, FCAHS, co-founder and CEO of Afynia
“It's 2023. There shouldn't be people wondering for five years what’s causing their pain.”
On average, women with endometriosis, a condition in which uterine tissue grows outside the uterus, will suffer for five to 12 years before receiving a proper diagnosis. An estimated 60% of cases are never diagnosed, resulting in decades of chronic pain, poor mental health, and potentially infertility.

Globally, one in ten women will suffer from endometriosis, a painful and debilitating gynecological condition. On average, women don’t get a proper diagnosis for five to twelve years after the onset of symptoms because, until now, the only reliable way to do so was via laparoscopic surgery that can cost over $20,000 and require three months of recovery. Moreover, endometriosis symptoms overlap with 25 other conditions, meaning undiagnosed women face years of costly trial-and-error treatment. 

Afynia has created the first and only patented blood test for diagnosing endometriosis early. It returns a result in days, not years, and will be offered through clinics and home collection kits beginning in 2024. Based on decades of research by co-founders Dr. Lauren Foster, PhD, and Dr. Jocelyn Wessels, PhD, former academics at McMaster University in Ontario, Canada, the endometriosis test is just the beginning. Afynia is building a digital women’s health platform that will provide diagnostics, virtual care, and prescription deliveries for endometriosis and other conditions. 

For too long, the world has normalized and undertreated chronic pelvic pain. With Afynia, women have the opportunity to become full-fledged partners in their own healthcare.